Interstitial lung disease, which prominently includes idiopathic pulmonary fibrosis, is a very broad category of chronic lung conditions with considerable nuance. To help break it down within the context of diagnosis and treatment, Dr. Marilyn Glassberg
at University of Arizona joins us to discuss the roles of biomarkers, biopsies and drugs. This episode also sheds light on multidisciplinary clinics and stem cell therapy.
Learn more about ILD and IPF at HCPLive.com